News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3124last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
MT Newswires10d agobullish
UBS Adjusts Price Target on Biogen to $300 From $270, Keeps Buy RatingMT Newswires10d agobullish
RBC Raises Price Target on Biogen to $272 From $256, Keeps Outperform RatingInsider Monkey54d agobullish
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades - Which Pharma Stock Has More Upside?MT Newswires75d agobullish
Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist SaysInvesting.com87d agobullish
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuationStockStory99d agobullish
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat OutlookInvestorsHub102d agobullish
Biogen Beats Second-Quarter Expectations as Growth Portfolio Drives Revenue HigherInvesting.com102d agobullish
Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts salesInvesting.com118d agobullish
Truist upgrades Biogen to Buy on Alzheimer’s, pipeline optimism ahead of key dataBarrons.com118d agobullish
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study DetailsInsider Monkey126d agobullish
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right NowBioPharma Dive143d agobullish
Biogen adds more immune drugs in $1B buyout of secretive startup RaytheraSimply Wall St.156d agobullish
Should Biogen’s (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors?Simply Wall St.156d agobullish
A Look At Biogen (BIIB) Valuation After New Breakthrough SMA Nod And Positive Lupus Phase 3 Data